How should side effects of bupropion be managed?

Management of Bupropion Side Effects

Monitor closely for neuropsychiatric symptoms and discontinue bupropion immediately if serious mood changes, suicidal ideation, or seizures occur; most common side effects like insomnia and dry mouth are mild, transient, and can be managed with dose reduction or symptomatic treatment. 1, 2

Monitoring Strategy

Neuropsychiatric Surveillance (Critical)

Close monitoring for neuropsychiatric adverse events is mandatory throughout treatment, regardless of psychiatric history. 1, 2

• Monitor for depression, suicidal ideation/behavior, anxiety, agitation, panic attacks, hostility, aggression, impulsivity, psychosis, hallucinations, paranoia, delusions, and mania 2
• These symptoms can occur in patients without pre-existing psychiatric disease 2
• Discontinue bupropion immediately if agitation, depressed mood, changes in behavior/thinking, suicidal ideation, or suicidal behavior develop 2
• Provide ongoing monitoring and supportive care until symptoms resolve, as symptoms may persist even after discontinuation 2
• Evidence from the EAGLES trial (n=8,058) showed neuropsychiatric adverse events with bupropion were not significantly increased versus placebo in patients with or without psychiatric disorders 1

Seizure Risk Management

Discontinue bupropion permanently if any seizure occurs. 2

• Seizure risk is dose-related; never exceed 300 mg daily for extended-release formulations 1, 2
• Incidence at recommended doses: approximately 0.1% (1/1,000 patients) 2
• Seizure risk increases nearly tenfold at doses between 450-600 mg/day 2
• Median seizure onset after therapeutic errors: 7 hours (range 2-21.5 hours) 3

Absolute contraindications (seizure-related): 1, 2

• Seizure disorder
• Brain metastases or CNS tumors
• Severe head injury or arteriovenous malformation
• Anorexia nervosa or bulimia
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs

Cardiovascular Monitoring

• Monitor blood pressure and heart rate, particularly in patients taking naltrexone-bupropion combinations 1
• Modest increases in systolic and diastolic blood pressure may occur in first 8 weeks, typically resolving by 12 weeks 1
• Avoid in patients with uncontrolled hypertension 1
• Tachycardia/palpitations reported in 5.5% of patients with therapeutic errors 4
• No significant increase in major cardiovascular adverse events versus placebo 1

Common Side Effect Management

Insomnia (Most Common)

Insomnia is the most frequently reported side effect but is generally transient. 1, 5

• Occurs significantly more often than placebo 1, 5
• Management approach:
  • Avoid late-day dosing; take second dose earlier in afternoon 1
  • Consider dose reduction if severe 1
  • Often resolves spontaneously without intervention 5
  • Note: Insomnia is also a nicotine withdrawal symptom in smoking cessation patients 1, 5

Nausea and Gastrointestinal Effects

Nausea is common, particularly with naltrexone-bupropion combinations, and is the most frequent reason for discontinuation. 1

• Nausea/vomiting led to discontinuation in 4.6-9.6% of patients in obesity trials 1
• Management approach:
  • Slow dose titration minimizes gastrointestinal side effects 1
  • Symptoms are generally transient 5
  • Consider dose reduction if persistent 1
• Constipation reported in 28.6% during buildup phase 6
• Severe constipation requiring surgical intervention has been reported rarely 7

Dry Mouth

• Occurs significantly more often than placebo 1, 5
• Generally transient and resolves without intervention 5
• Can be managed with dose reduction if bothersome 5

Headache and Dizziness

• Common but typically mild 1, 5
• Headache reported in 0.9-1.8% as reason for discontinuation 1
• Usually self-limited 5

Dose Adjustment Strategies

Standard Titration for Smoking Cessation

Gradual dose escalation reduces adverse events. 1

• Days 1-3: 150 mg once daily
• Day 4 onward: 150 mg twice daily if tolerated
• Maximum: 300 mg per day
• Initiate 1-2 weeks prior to quit date 1

Dose Modifications for Special Populations

Renal impairment: 1

• Moderate to severe: Reduce total daily dose by half (e.g., 1 tablet twice daily for naltrexone-bupropion)
• End-stage renal disease: Avoid use

Hepatic impairment: 1

• Moderate to severe: Do not exceed 1 tablet daily for naltrexone-bupropion

When to Reduce or Discontinue

• Reduce dose if common side effects (insomnia, dry mouth, nausea) are bothersome but tolerable 1, 5
• Discontinue immediately for: 2
  • Any seizure
  • Serious neuropsychiatric symptoms
  • Severe hypersensitivity reactions (incidence ~0.1%) 5
  • Severe allergic reactions including urticaria and angioedema 8

Drug Interactions and Contraindications

Absolute Contraindications

Do not use bupropion in patients with: 1, 2

• Seizure disorders or conditions increasing seizure risk
• Current or recent (within 14 days) MAO inhibitor use (risk of hypertensive reactions)
• Closed-angle glaucoma
• Concurrent tamoxifen use (for smoking cessation formulations)
• Patients requiring short- or long-term opiate therapy (for naltrexone-bupropion combinations) 1

Medications That Lower Seizure Threshold

Use extreme caution or avoid with: 2

• Other bupropion products
• Antipsychotics
• Tricyclic antidepressants
• Theophylline
• Systemic corticosteroids
• CNS stimulants

Discontinuation Rates and Outcomes

• Overall discontinuation due to adverse events: 6-12% in clinical trials 5
• In obesity trials: 25% discontinued due to adverse effects versus 10% with placebo 1
• In real-world obesity settings: 52.7% discontinued within 12 months (multiple reasons including side effects) 6
• Most adverse effects are mild (no effect 50.1%, minor 45.5%, moderate 4.4%) 3

Special Considerations

Sexual Dysfunction

Bupropion has significantly lower rates of sexual adverse events compared to SSRIs. 1

• Lower sexual dysfunction than fluoxetine or sertraline 1
• May be preferred in patients concerned about sexual side effects

Weight Effects

• Unlike many antidepressants, bupropion is associated with weight loss rather than weight gain 1
• Approved in combination with naltrexone for chronic weight management 1

Formulation Switching

• If severe hypersensitivity reaction occurs with one formulation (e.g., XL), trial of alternative formulation (e.g., SR) may be tolerated 8
• Different formulations may have different tolerability profiles